Summary: Peginterferon/Ribavirin-Experienced, Genotype 3 Patients Without Cirrhosis
Recommended and alternative regimens listed by evidence level and alphabetically for:
Peginterferon/Ribavirin-Experienced, Genotype 3 Patients Without Cirrhosis
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)a
|
12 weeks
|
I, A
|
|
ALTERNATIVE
|
DURATION
|
RATING
|
|
Daily daclatasvir (60 mg)b plus sofosbuvir (400 mg)a
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)c
|
16 weeks
|
IIa, B
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) when Y93H is present
|
12 weeks
|
IIb, B
|
a Baseline RAS testing for Y93H is recommended. If the Y93H substitution is identified, a different regimen should be used, or weight-based ribavirin should be added as an alternative option.
b The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. Please refer to the prescribing information and the section on HIV/HCV coinfection for patients on antiretroviral therapy.
c This is a 3-tablet coformulation. Please refer to the prescribing information.
|
